Kramer, Christopher M.

2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines

Isselbacher, E. M., Preventza, O., Hamilton Black, J., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., et al. (2022) · Circulation

Aortic Disease and Treatment ApproachesConnective tissue disorders research

Cited by 2,082

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation

Ferreira, V. M., Schulz-Menger, J., Holmvang, G., Kramer, C. M., Carbone, I., Sechtem, U., Kindermann, I., Gutberlet, M., Cooper, L. T., Liu, P., et al. (2018) · Journal of the American College of Cardiology

Viral Infections and Immunology ResearchCardiac Imaging and Diagnostics

Cited by 2,059

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet

Cardiomyopathy and Myosin StudiesBlood Pressure and Hypertension Studies

Cited by 1,296

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,009

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology

Cardiovascular Disease and AdiposityHeart Failure Treatment and Management

Cited by 200

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 166

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 74

Plaque composition in the proximal superficial femoral artery and peripheral artery disease events

McDermott, M. M., Kramer, C. M., Tian, L., Carr, J., Guralnik, J. M., Polonsky, T., Carroll, T., Kibbe, M., Criqui, M. H., Ferrucci, L., et al. (2017) · JACC: Cardiovascular Imaging

Peripheral Artery Disease ManagementAtherosclerosis and Cardiovascular Diseases

Cited by 55

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 49

A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers

Dhingra, L. S., Sangha, V., Aminorroaya, A., Bryde, R., Gaballa, A., Ali, A. H., Mehra, N., Krumholz, H. M., Sen, S., Kramer, C. M., et al. (2025) · The American Journal of Cardiology

Cardiomyopathy and Myosin StudiesECG Monitoring and Analysis

Cited by 18